山东威高骨科材料股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a preliminary financial performance for the year 2025, indicating growth in revenue and net profit, driven by strategic adjustments in sales and ongoing investment in research and development [1][3][4]. Financial Data and Indicators - The company achieved an operating revenue of 153,919.23 million RMB, representing a year-on-year increase of 5.95% [3]. - The net profit attributable to the parent company was 26,663.92 million RMB, up 19.17% from the previous year [3]. - The net profit after deducting non-recurring gains and losses was 25,218.28 million RMB, reflecting a growth of 19.59% [3]. - Excluding stock payment expenses, the adjusted net profit was approximately 29,564 million RMB, marking a growth of about 32.13% [3]. - Total assets at the end of the reporting period were 506,999.15 million RMB, a 2.46% increase from the beginning of the period [4]. - The equity attributable to the parent company was 414,357.79 million RMB, up 4.81% [4]. - The net asset per share attributable to the parent company was 10.36 RMB, also reflecting a 4.81% increase [4]. Operational Performance and Financial Condition - The company experienced stable execution of orthopedic bulk procurement, with leading domestic brands increasing their market share [5]. - Sales strategies were enhanced through adjustments in sales models and organizational structure, focusing on professional departments to boost profitability [5]. - The company segmented its product lines and improved the professional capabilities of its sales team, leading to increased clinical service precision and academic leadership [5]. - There was a notable increase in business from key hospitals and a focus on developing lower-tier markets and promoting innovative products, contributing to sustained growth in surgical volume and revenue [5]. - Continuous investment in R&D was maintained, particularly in orthopedic biomaterials, intelligent devices, and minimally invasive consumables, fostering innovation in new orthopedic products [5]. - The company also emphasized the localization of raw materials and improvements in R&D processes to enhance quality and reduce costs [5]. - Digital transformation efforts were made to improve supply chain efficiency and reduce costs through refined management practices, resulting in rapid net profit growth [6].